These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 9923536

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK.
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Disposition of amphotericin B in the isolated perfused rat liver.
    Hong Y, Ramzan I, McLachlan AJ.
    J Pharm Pharmacol; 2004 Jan 16; 56(1):35-41. PubMed ID: 14979999
    [Abstract] [Full Text] [Related]

  • 9. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.
    Br J Cancer; 1999 Sep 16; 81(2):330-5. PubMed ID: 10496361
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Jul 16; 50(1):16-24. PubMed ID: 12111107
    [Abstract] [Full Text] [Related]

  • 13. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens J, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2002 Feb 16; 49(2):119-25. PubMed ID: 11862425
    [Abstract] [Full Text] [Related]

  • 14. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N.
    Clin Cancer Res; 2005 Jun 01; 11(11):4136-43. PubMed ID: 15930349
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X, Sun J, Chen X, Wang S, Scott H, Zhang X, Zhang Q.
    J Pharm Pharmacol; 2012 Jun 01; 64(6):775-82. PubMed ID: 22571255
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
    Fransson MN, Gréen H, Litton JE, Friberg LE.
    Drug Metab Dispos; 2011 Feb 01; 39(2):247-55. PubMed ID: 21056987
    [Abstract] [Full Text] [Related]

  • 18. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.